Lv31
300 积分 2024-06-11 加入
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
1个月前
已完结
A Formalin-Fixed, Paraffin-Processed Cell Line Standard for Quality Control of Immunohistochemical Assay of HER-2/neu Expression in Breast Cancer
2个月前
已完结
Standardization of Positive Controls in Diagnostic Immunohistochemistry
2个月前
已完结
Effect of Ischemic Time, Fixation Time, and Fixative Type on HER2/neu Immunohistochemical and Fluorescence In Situ Hybridization Results in Breast Cancer
2个月前
已完结
Impact of immunohistochemistry staining conditions on the incidence of human epidermal growth factor receptor 2 (HER2)-low breast cancer
2个月前
已完结
Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France
3个月前
已完结
Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis
3个月前
已完结
PD‐L1 immunohistochemistry: Clones, cutoffs, and controversies
3个月前
已完结
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation
3个月前
已完结
PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy
3个月前
已完结
皖公网安备34019202002308
